Mavacoxib
Appearance
![]() | |
Clinical data | |
---|---|
Trade names | Trocoxil |
AHFS/Drugs.com | International Drug Names |
ATCvet code | |
Identifiers | |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEBI | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.248.948 |
Chemical and physical data | |
Formula | C16H11F4N3O2S |
Molar mass | 385 g/mol g·mol−1 |
3D model (JSmol) | |
| |
|
Mavacoxib (trade name Trocoxil) is a veterinary drug used to treat pain and inflammation in dogs with degenerative joint disease.[1] It acts as a COX-2 inhibitor.[2]
Mavacoxib, along with other COX-2 selective inhibitors, celecoxib, valdecoxib, and parecoxib, were discovered by a team at the Searle division of Monsanto led by John Talley.[3][4]
References
- ^ European Public Assessment Report (EPAR): Trocoxil, European Medicines Agency
- ^ Cox, S. R.; Lesman, S. P.; Boucher, J. F.; Krautmann, M. J.; Hummel, B. D.; Savides, M.; Marsh, S.; Fielder, A.; Stegemann, M. R. (2010). "The pharmacokinetics of mavacoxib, a long-acting COX-2 inhibitor, in young adult laboratory dogs". Journal of Veterinary Pharmacology and Therapeutics. 33 (5): 461–70. doi:10.1111/j.1365-2885.2010.01165.x. PMID 20840390.
- ^ Langreth, Robert (June 23, 2003). "The Chemical Cobbler". Forbes.
- ^ "Dr. John Talley: 2001 St. Louis Awardee" (PDF). Chemical Bond. 52 (5). St. Louis Section, American Chemical Society: 2. May 2001. Archived from the original (PDF) on 15 April 2018.